

## Drug Corner

Oral Phosphate Binders(PB) alone are insufficient to control Hyperphosphatemia in patients on Hemodialysis. Nicotinamide Modified-Release Formulation (NAMR) combined with oral PB significantly improved phosphate control in hemodialysis patients.

Markus Ketteler, Richard Ammer

<https://doi.org/10.1016/j.ekir.2020.12.012>

Finerenone, a novel selective, nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of clinically important cardiovascular and kidney outcomes vs. placebo across the spectrum of CKD in patients with type 2 diabetes.

European Heart Journal, ehab777, <https://doi.org/10.1093/eurheartj/ehab777>

Published: 22 November 2021

*Dr. R. Rajasekar, Kumbakonam*